The Relationship Between Prostate Cancer and Cardiovascular Disease

Experts on prostate cancer discuss the relationship between prostate cancer and cardiovascular disease, highlighting ongoing research for safer treatment.

EP: 1.Prostate Cancer Treatment: The Evolving Therapeutic Landscape

EP: 2.The Heterogeneity of Prostate Cancer

EP: 3.The Role of ADT in Localized or Locally Advanced Prostate Cancer

EP: 4.EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

EP: 5.Treatment Considerations in Nonmetastatic CSPC

EP: 6.Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

EP: 7.Treatment Options in Castration-Resistant Prostate Cancer

Now Viewing

EP: 8.The Relationship Between Prostate Cancer and Cardiovascular Disease

EP: 9.Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

EP: 10.ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Related Videos

Related Content

Advertisement

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

Related Content

Advertisement

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.